Phoenix Biotech Acquisition Corp.
PBAX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $2,386 | $2,754 | $2,908 | $7,080 |
| G&A Expenses | $1,976 | $1,970 | $2,043 | $6,600 |
| SG&A Expenses | $1,976 | $1,970 | $2,043 | $6,600 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$2 |
| Operating Expenses | $4,363 | $4,724 | $4,951 | $13,680 |
| Operating Income | -$4,363 | -$4,724 | -$4,951 | -$14,494 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7,144 | -$25,394 | -$504 | $5,588 |
| Pre-Tax Income | -$11,506 | -$30,118 | -$5,454 | -$8,906 |
| Tax Expense | $0 | $0 | $0 | $38 |
| Net Income | -$11,506 | -$30,118 | -$5,454 | -$8,944 |
| % Margin | – | – | – | – |
| EPS | -9.1 | -61.71 | -0.11 | -0.18 |
| % Growth | 85.3% | -56,000% | 38.9% | – |
| EPS Diluted | -9.1 | -61.71 | -0.11 | -0.18 |
| Weighted Avg Shares Out | 1,265 | 488 | 49,676 | 49,676 |
| Weighted Avg Shares Out Dil | 1,265 | 488 | 49,676 | 49,676 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$381 |
| Interest Expense | $6 | $14 | $1 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $696 |
| EBITDA | -$4,363 | -$4,724 | -$4,951 | -$8,210 |
| % Margin | – | – | – | – |